Anaptysbio (ANAB) Net Cash Flow (2016 - 2026)
Anaptysbio filings provide 11 years of Net Cash Flow readings, the most recent being $10.3 million for Q1 2026.
- On a quarterly basis, Net Cash Flow rose 142.03% to $10.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $149.8 million, a 233.39% increase, with the full-year FY2025 number at $115.1 million, up 32.14% from a year prior.
- Net Cash Flow hit $10.3 million in Q1 2026 for Anaptysbio, down from $128.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $128.4 million in Q4 2025 to a low of -$329.3 million in Q1 2022.
- Median Net Cash Flow over the past 5 years was $9.7 million (2023), compared with a mean of -$14.5 million.
- Biggest five-year swings in Net Cash Flow: crashed 1077.43% in 2022 and later skyrocketed 1443.96% in 2024.
- Anaptysbio's Net Cash Flow stood at $12.8 million in 2022, then decreased by 24.22% to $9.7 million in 2023, then plummeted by 808.39% to -$68.5 million in 2024, then surged by 287.39% to $128.4 million in 2025, then tumbled by 92.0% to $10.3 million in 2026.
- The last three reported values for Net Cash Flow were $10.3 million (Q1 2026), $128.4 million (Q4 2025), and $65.5 million (Q3 2025) per Business Quant data.